Every letter we have printed

Adducts deserve a paragraph. Sodium and potassium are everywhere in glassware and buffers, they shift the observed mass by amounts that look meaningful, and an analyst who is not expecting them can report a modification that is really a salt. It is the most common false positive I see in this trade.

The monoisotopic against average distinction is the one I spend most time explaining. Below about two kilodaltons the monoisotopic peak is the one you can see and the one you should quote. Above it the isotope envelope broadens until the average is the honest description, and a certificate quoting a monoisotopic mass for a large peptide is quoting a peak nobody resolved.

Any transposition of two residues preserves the intact mass exactly. So does a substitution that swaps one residue for another of the same composition. The set of molecules consistent with a given mass is not small, and describing a mass match as identity confirmation makes a claim about that whole set.

The claim that a reproduced spectrum is worth more than any number in the document seems overstated. Most buyers cannot read a spectrum, and a printed image invites false confidence rather than scrutiny.

You might state plainly that absorbance at the peptide bond is not uniform across sequences either. Two impurities present at the same molar concentration will give different areas if one carries an extra tryptophan, and at 214 nanometres the backbone dominates but does not monopolise. Area per cent is an approximation twice over.

The wavelength section is the part of this series I have found most useful in practice. A supplier sent us a certificate reading at 280 nanometres for a sequence with a single tyrosine, and once we asked for 214 nanometres the impurity profile looked entirely different. Nobody had done anything improper. The method simply could not see what we needed to see.

Gallbladder-related findings follow rapid weight loss from any cause and are not specific to any pharmacology. Attributing them to the agent rather than to the rate of loss is a common error and the distinction matters for what somebody does next. This is not medical advice.

Panel names imply organ specificity that the analytes do not have. Several of the markers in a liver panel are produced elsewhere and rise for reasons unconnected with that organ, which is why the panel is read as a pattern rather than item by item.

Biological variation within one person is smaller than the variation between people for many analytes, which is why a series of results on one individual is far more informative than a single result against a population interval.

You give the reference change value for ALT as about sixty per cent, which strikes me as so large as to make routine monitoring of it pointless. Is that your position?

Intervals are periodically revised, and a laboratory that changes its interval will produce an apparent change in a patient whose biology did not move. The revision date is on the report and nobody reads it.

An accreditation body will investigate a complaint about a laboratory within its scope. Almost nobody in this market knows that, and I would put the route in a sidebar: it is free, it is real, and it is used vanishingly rarely.

What happens when a certificate turns out to be wrong is the question your article stops short of. In a regulated setting a corrected document is reissued to everyone who received the original. Elsewhere it is corrected for whoever complained, and the original stays in circulation. That asymmetry is worth a piece of its own.

On the accreditation-scope point: most private buyers will not know which accreditation body to search. It would be more useful to publish the four or five registers that cover the laboratories this market actually uses than to tell readers the registers exist.

A certificate for a molecule is not a certificate for a vial. Where a supplier publishes one document per product rather than one per lot, the document is marketing with a chromatogram attached, however genuine the underlying determination was.

Nine years buying research chemicals and I had never once looked at the date of manufacture. I checked eleven certificates in my drawer this evening. Four do not carry one.

Near misses are more informative than events and are almost never described, because nothing happened. In every other safety-critical field the near miss is the primary data source.

Reconstituting with the wrong volume and then calculating from the intended volume is the second error, and it is invisible afterwards because the vial looks identical. Writing the actual diluent volume on the vial with a marker takes three seconds and closes it.

The convenient reconstitution is the one that makes the arithmetic trivial rather than the one that makes the volume small. Choosing a diluent volume so that a graduation corresponds to a round figure removes an entire class of error, and it costs nothing but a moment’s thought before the needle goes in.

Reuse is discussed as a sterility question and is also a mechanical one. A needle point deforms on first use in a way that is visible under magnification, and the deformation is what causes the second use to be different.

As a practice nurse I would add the ten-second hold to your list of things people skip. I watch patients withdraw immediately and then wonder about the wet patch on their skin. It is the most visible underdose there is and almost nobody connects the two.

Monitoring intensity almost always falls during a long stable phase, which means the period with the least data is the period lasting longest. Anybody reading a personal series should know that the flat part is flat partly because nobody was looking.

Cost is the maintenance variable that never appears in a trial protocol and dominates every real decision. An indefinite commitment priced monthly is a different proposition from a course of treatment, and the literature is written as though the two were the same shape.

A methodological complaint. Asking somebody for their reason implies there was one. Several of the most honest accounts I have read describe a drift rather than a decision, and a questionnaire with a list of reasons will never capture that.

The reporting convention that irritates me most is the pie chart. Reasons are not mutually exclusive, they are not equally weighted, and a shape that implies both is doing damage to the reader’s understanding before a single number is read.

There is a selection effect in every maintenance dataset. The people still in the study at month thirty are the people for whom it worked, and any statement about maintenance derived from them describes that subgroup rather than the original population.

I have read this department for two years and the finding that has stayed with me is how little of the long-horizon question anybody has actually studied. That is not a criticism of the coverage; it is the coverage’s main result.

The physiology of regain after any weight loss is well described and predates all of this pharmacology by decades. Presenting it as a novel finding about these agents misplaces a body of work that would help readers understand what they are seeing.

I lost access for eleven weeks during the shortage, restarted at the dose I had been on because nobody told me otherwise, and spent a fortnight unable to keep food down. I had been on that dose for seven months without difficulty. Reading your resumption section was the first time anybody explained it.

Regain curves are usually plotted from the point of withdrawal, which flatters them. Plotted from baseline they show something else entirely, and the choice of origin is a presentational decision with a large effect on the impression.

Albumin binding modifies the free fraction and therefore what actually reaches the receptor, and it differs substantially between the compounds under discussion. Potency comparisons that ignore it are comparing the wrong quantity.

The class B receptor architecture is worth a diagram for readers who last saw this at university. A large extracellular domain that captures the peptide, then a second interaction with the transmembrane core: it explains immediately why these are peptides and not tablets, and why the small-molecule agonists that do exist had to solve a different problem.

The central and peripheral contributions are separable in animal work and not in human studies, and coverage tends to attribute everything to whichever the writer finds more intuitive. The honest statement is that both are implicated and the proportion is unknown.

Tachyphylaxis in the emptying effect is well described and rarely mentioned outside the specialist literature. A mechanism that attenuates over weeks explains a great deal of the time course that otherwise looks mysterious.

I would like badges to carry a date in the image itself, not in a tooltip and not in a linked report. Anything that requires a second click will not be clicked, and a design that depends on diligence the reader does not have is a design that has chosen its outcome.

What a badge cannot do is carry forward in time. A report on a lot filled eighteen months ago says nothing about the lot shipping today, and the badge sits in the page template rather than on the product. Verification has a date and the design of these things hides it.

Freight is the confounder nobody controls for. Two vials from the same lot, one shipped in January and one in July, are not the same sample by the time they reach an instrument, and a blind programme that ignores the season is measuring the courier as much as the manufacturer.

The report format is part of the product and it is priced as though it were not. A one-page summary and a full package with the chromatogram, the suitability data and the audit trail cost the laboratory very different amounts of attention, and most price lists distinguish them by a few pounds.

Thank you for this. It answered the question I came with and raised two I had not thought to ask.

The pathways that matter for potency and the pathways that matter for immunogenicity are not the same set, and only the first is discussed in this market at all. The second is a proper research question and not a topic for speculation.